An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Trial Profile

An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs MDNA 55 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Medicenna Therapeutics
  • Most Recent Events

    • 12 Feb 2018 According to a Medicenna Therapeutics media release, enrolment is expected to be completed by by mid-2018.
    • 21 Dec 2017 Planned End Date changed from 1 Dec 2018 to 1 Jul 2018.
    • 21 Dec 2017 Planned primary completion date changed from 1 Nov 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top